Cargando…
Proof-of-Concept, Randomized, Controlled Clinical Trial of Bacillus-Calmette-Guerin for Treatment of Long-Term Type 1 Diabetes
BACKGROUND: No targeted immunotherapies reverse type 1 diabetes in humans. However, in a rodent model of type 1 diabetes, Bacillus Calmette-Guerin (BCG) reverses disease by restoring insulin secretion. Specifically, it stimulates innate immunity by inducing the host to produce tumor necrosis factor...
Autores principales: | Faustman, Denise L., Wang, Limei, Okubo, Yoshiaki, Burger, Douglas, Ban, Liqin, Man, Guotong, Zheng, Hui, Schoenfeld, David, Pompei, Richard, Avruch, Joseph, Nathan, David M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3414482/ https://www.ncbi.nlm.nih.gov/pubmed/22905105 http://dx.doi.org/10.1371/journal.pone.0041756 |
Ejemplares similares
-
Bacillus Calmette-Guerin 's beneficial impact on glucose metabolism: evidence for broad based applications
por: Shpilsky, Gabriella F., et al.
Publicado: (2021) -
Bacillus Calmette–Guérin Immunotherapy for Cancer
por: Cardillo, Fabíola, et al.
Publicado: (2021) -
VARIABILITY OF BCG STRAINS (BACILLUS CALMETTE-GUÉRIN)
por: Suter, W. Emanuel, et al.
Publicado: (1951) -
Disseminated Bacillus Calmette-Guérin Infection and Immunodeficiency
por: Bernatowska, Ewa Anna, et al.
Publicado: (2007) -
Bacillus Calmette-Guerin (BCG) vaccine in Iran
por: Fallah, Fatemeh, et al.
Publicado: (2018)